Spero Therapeutics (SPRO) Receivables - Net (2023 - 2025)
Spero Therapeutics (SPRO) has disclosed Receivables - Net for 3 consecutive years, with $868000.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Receivables - Net fell 98.28% year-over-year to $868000.0, compared with a TTM value of $868000.0 through Sep 2025, down 98.28%, and an annual FY2024 reading of $49.4 million, changed 0.49% over the prior year.
- Receivables - Net was $868000.0 for Q3 2025 at Spero Therapeutics, down from $24.5 million in the prior quarter.
- Across five years, Receivables - Net topped out at $50.8 million in Q2 2024 and bottomed at $868000.0 in Q3 2025.
- Average Receivables - Net over 3 years is $37.3 million, with a median of $49.2 million recorded in 2023.
- The sharpest move saw Receivables - Net rose 0.49% in 2024, then plummeted 98.28% in 2025.
- Year by year, Receivables - Net stood at $49.2 million in 2023, then rose by 0.49% to $49.4 million in 2024, then plummeted by 98.24% to $868000.0 in 2025.
- Business Quant data shows Receivables - Net for SPRO at $868000.0 in Q3 2025, $24.5 million in Q2 2025, and $23.6 million in Q1 2025.